By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Stem Cell Research have been published. According to news reporting out of Hangzhou, People's Republic of China, by NewsRx editors, research stated, "HERV-K (human endogenous retrovirus type K) type 1-encoded Np9 is a tumor-specific biomarker, but its oncogenic role and targets in human leukemia remain elusive. We first identified Np9 as a potent viral oncogene in human leukemia."
Our news journalists obtained a quote from the research from Zhejiang University, "Silencing of Np9 inhibited the growth of myeloid and lymphoblastic leukemic cells, whereas expression of Np9 significantly promoted the growth of leukemia cells in vitro and in vivo. Np9 not only activated ERK, AKT and Notch1 pathways but also upregulated ?-catenin essential for survival of leukemia stem cells. In human leukemia, Np9 protein level in leukemia patients was substantially higher than that in normal donors (56% vs 4.5%). Moreover, Np9 protein level was correlated with the number of leukemia stem/progenitor cells but not detected in normal CD34(+) hematopoietic stem cells. In addition, Np9-positive samples highly expressed leukemia-specific pol-env polyprotein, env and transmembrane proteins as well as viral particles. Thus, the viral oncogene Np9 is a critical molecular switch of multiple signaling pathways regulating the growth of leukemia stem/progenitor cells."
According to the news editors, the research concluded: "These findings open a new perspective to understand the etiology of human common leukemia and provide a novel target for treating leukemia."
For more information on this research see: The viral oncogene Np9 acts as a critical molecular switch for co-activating ?-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells. Leukemia, 2013;27(7):1469-78. (Nature Publishing Group - www.nature.com/; Leukemia - www.nature.com/leu/)
Our news journalists report that additional information may be obtained by contacting T. Chen, Dept. of Hematology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Taiwan. Additional authors for this research include Z. Meng, Y. Gan, X. Wang, F. Xu, Y. Gu, X. Xu, J. Tang, H. Zhou, X. Zhang, X. Gan, C. Van Ness, G. Xu, L. Huang, X. Zhang, Y. Fang, J. Wu, S. Zheng, J. Jin, W. Huang and R. Xu (see also Stem Cell Research).
Keywords for this news article include: Asia, Viral, Virus, Hangzhou, Genetics, Leukemia, Oncology, Hematology, Nanotechnology, Molecular Switches, Stem Cell Research, Emerging Technologies, People's Republic of China.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC